Anti-retroviral efficacy, tolerance and other pharmacologic interactions of the non nucleoside analog efavirenz in association with rifampicin to treat tuberculosis and AIDS.

Trial Profile

Anti-retroviral efficacy, tolerance and other pharmacologic interactions of the non nucleoside analog efavirenz in association with rifampicin to treat tuberculosis and AIDS.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2015

At a glance

  • Drugs Efavirenz (Primary) ; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IPEC-EFV
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 23 Jul 2010 Results in 63 patients reported at 18th International AIDS Conference.
    • 03 Nov 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top